Studies so far carried out to exhibit the effect of Tasigna as an active therapeutic molecule for the neurodegenerative disease is in concern with C-ABL inhibition and some studies are also focused on autophagic clearance of α-SYNUCLEIN and amyloid aggregates in Parkinson’s and Alzheimer’s disease respectively. The gene discussed is ABL1; the disease is early-onset autosomal dominant Alzheimer disease.